[Current development in the diagnostics and therapy of systemic fungal infections in cancer patients].
Invasive fungal infections are associated with a high morbidity and mortality. They are of growing concern and a severe infectious complication in cancer patients treated with intensive chemotherapy. Within the last five years substantial progress has been demonstrated for non-culture based diagnostics and treatment of invasive fungal infections. Recent developments in the epidemiology, diagnostics and treatment of fungal infections are reviewed and discussed in the context of the current state of art for the management of invasive fungal infections in cancer patients.
Karthaus
Meinolf
M
Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Johannes Krankenhaus, Bielefeld, Deutschland. Meinolf-Karthaus@johanneswerk.de
Ullmann
Andrew J
AJ
Cornely
Oliver A
OA
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D000946:Antigens, Fungal / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy; D002648:Child; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D016533:Mycological Typing Techniques; D009181:Mycoses / Q000175:diagnosis* / Q000188:drug therapy; D009369:Neoplasms / Q000628:therapy*; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy; D010166:Palliative Care; D016133:Polymerase Chain Reaction; D033581:Stem Cell Transplantation
D000935:Antifungal Agents; D000946:Antigens, Fungal; D000970:Antineoplastic Agents